



(Use as many sheets as necessary)

Complete if Known

Application Number	10/701,870
Filing Date	11/05/2003
First Named Inventor	Fritz Sieber
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	650053.91649

[illegible][illegible]

03.11.05

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/701,870		
		Filing Date	11/05/2003		
		First Named Inventor	Fritz Sieber		
		Art Unit	1645		
Examiner Name	N/A				
Sheet	2	of	3	Attorney Docket Number	650053.91649

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WT	2	Günther WHH, Searle R. and Sieber F; Structure-Activity Relationships in the Antiviral and Antileukemic Photoproperties of Merocyanine Dyes; Seminars in Hematology, Vol. 29, No. 2, pp. 88-94, 1992.	
1	3	Günther WHH, Searle R and Sieber F; Photosensitizing Merocyanine Dyes Based on Selenobarbituric Acid; Phosphorus, Sulfur, and Silicon, Vol. 67: pp. 417-424, 1992.	
	4	Krieg M, Bilitz JM, Traul DL and Sieber F; Photosensitizing Oxonol Dyes with Antineoplastic Activity, Cancer Research, Therapy and Control, Vol. 4, pp. 163-172, 1995.	
	5	Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH: Pre-Clinical Evaluation of a Methotrexate-Albumin Conjugate (MTX-HSA) in Human Tumor Xenografts In Vivo; Int. J. Cancer. 92, 718-724, 2001.	
	6	Wunder A, Müller-Ladner U, Stelzer EHK, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C; Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis; The Journal of Immunology, 170, 4793-4801, 2003.	
	7	Yan L, Yee JA, Boylan LM, Spallholz JE; Effect of Selenium Compounds and Thiols on Human Mammary Tumor Cells, Biological Trace Element Research, Vol 30, pp. 145-162, 1991.	
	8	Zhang J-S, Gao X-Y, Zhang L-D, Bao Y-P; Biological effects of a nano red elemental selenium, BioFactors 16, 27-38, 2001.	
	9	Huang B, Zhang J, Hou J, Chen C; Free Radical Scavenging Efficiency of Nano-Se In Vitro; Free Radical Biology & Medicine, Vol. 35, No. 7, pp. 805-813, 2003.	
	10	Sieber F, Daziano J-P, Anderson GS, Miyagi K, Sampson RW, Tsujino I, Günther WHH, Krieg M, Bousbaa J and Försterling FH; Colloidal Selenium Generated by Photobleaching of Selenomercocyanine Dyes Combines with Serum Macromolecules to Form Conjugates that are Preferentially Cytotoxic to Leukemia and Selected Solid Tumor Cells; Blood 100, 224b, 2002.	
Y	11	Miyagi K, Sampson RW, Tsujino I, Günther WHH, Krieg M and Sieber F; Proteinated subnanoparticles of elemental selenium potentiate the anti-tumor effect of ionizing radiation and selected chemotherapeutic agents; Proceedings of the American Association Cancer Research, Vol. 44, 385, 2003.	

Examiner Signature		Date Considered	03.11.05
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/701/870
Filing Date	11/05/2003
First Named Inventor	Fritz Sieber
Group Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	650053.91649

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RT.	12	Sieber F; Proteinated Subnanoparticles of Colloidal Selenium: A New Class of Anti-Leukemia/Lymphoma Agents; Leukemia 17: 683, 2003.	
RT.	13	Oral Presentation at 32nd Annual Scientific Meeting of the International Society for Experimental Hematology, Paris (France), July 7, 2003.	

Examiner Signature		Date Considered	03.11.05
-----------------------	--	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.